NCT07903246Recruiting
A Prospective Study of Anxiety, Depression, and Bipolar Disorder in People
A Prospective Cohort Study of Emotion-Related Disorders
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
This study aims to understand how anxiety disorders, depressive disorders, and bipolar disorder change over time and to identify patterns that may help with earlier recognition, diagnosis, and prediction of future symptoms. The study will enroll approximately 2,690 participants aged 12 to 55 years across multiple hospitals in China. Participants will include people with anxiety disorders, depressive disorders, or bipolar disorder, as well as healthy volunteers for comparison. Participants will be followed for 3 years after enrollment, with assessments at baseline and at 1, 6, 12, 18, 24, 30, and 36 months. Study assessments will collect information about symptoms, treatment, daily functioning, and quality of life. Other study data will include biological samples, brain imaging, recordings of brain electrical activity, and measurements from wearable devices and tasks involving speech, facial expressions, and eye movements. Researchers will examine how these measurements relate to symptoms and changes in health over time. They will also develop and evaluate artificial intelligence models intended to help identify these disorders and predict treatment outcomes, relapse, and suicide or self-harm risk. This is an observational study. The researchers will not assign treatments or change participants' treatment as part of the study. Treatments received during routine clinical care will be recorded.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2690 (estimated)
- First submitted
- 7 Oct 2026
- Start date
- 15 Sept 2026
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Bipolar disorder
- NCT number
- NCT07903246
What you commit to
- Study type: Observational
- Planned participants: 2690
- From 15 Sept 2026 to the primary completion date, 31 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or previous organic brain disease, a history of epilepsy, or a history of traumatic brain injury.
- Electroconvulsive therapy, transcranial magnetic stimulation, alternating-current or direct-current electrical stimulation, vagus nerve stimulation, or deep brain stimulation within the previous 6 months.
- Metal implants or other metallic objects that cannot be safely removed and prevent safe magnetic resonance imaging.
Other illness
- Failure to meet the inclusion criteria for the relevant group, or meeting DSM-5 criteria for a mental disorder other than those targeted by this study.
- A history of drug or substance abuse, including tobacco, alcohol, or other psychoactive substances.
- Cardiovascular, cerebrovascular, respiratory, or neurological disease; infectious disease; other serious physical illness; or a pathological condition that may cause cognitive impairment.
- Any other condition that, in the investigator's judgment, makes participation unsuitable.
Other
- The following criteria apply to all groups:
- Current risk of dangerous behavior, rated as level 2 or above on the dangerousness assessment specified in the protocol.
- Severe agitation, oppositional behavior, or markedly reduced volition or activity that prevents completion of the assessments.
- Limb disability or inability to make the required button-press responses using the upper limbs.
- Pregnancy or breastfeeding.
- Red-green color blindness.
Who the study is looking for
- General criteria for all groups:
- Age 12 to 55 years, inclusive, of any sex.
- Education at or above the third-grade primary school level.
- Voluntary participation with written informed consent. For participants younger than 18 years, written informed consent from a legal guardian and the participant's assent, when capable, are required. For participants with impaired consent capacity, consent will be obtained from the participant and/or legal guardian as specified in the protocol.
- Anxiety disorders group:
- Meet DSM-5 diagnostic criteria for one or more anxiety spectrum disorders.
- Hamilton Anxiety Rating Scale (HAMA-14) total score of at least 14.
- Normal intellectual functioning, vision, and hearing.
- Depressive disorders group:
- Meet DSM-5 diagnostic criteria for one or more depressive disorders.
- Hamilton Depression Rating Scale (HAMD-17) total score of at least 17.
- Normal intellectual functioning, vision, and hearing.
- Bipolar disorder group:
- Meet DSM-5 diagnostic criteria for bipolar I or bipolar II disorder.
- Not currently experiencing a manic episode.
- Normal intellectual functioning, vision, and hearing.
- Healthy control group:
- Normal or corrected-to-normal vision.
- Good physical health, without serious physical illness or chronic disease.
- Normal cognitive functioning.
- No family history of mental illness across three generations on either the maternal or paternal side.
Age in the registry: 12 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Second Affiliated Hospital,School of Medicine,Zhejiang University Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.